Group 1 - Bank of America has lowered the target price for Novavax from $9 to $7, changing its rating from "Neutral" to "Underperform" [2] - Citigroup has initiated coverage on Novavax with a "Sell" rating and a target price of $6 [2]

Group 1 - The stock of the company, CSPC Pharmaceutical Group, fell over 5%, marking the largest decline in three weeks [1] - Jefferies downgraded the stock rating to "underperform," indicating that all positive factors have already been reflected in the stock price [1] - The company continues to face sales challenges for key products [1]

Core Viewpoint - Iovance Biotherapeutics experienced a nearly 6% decline in stock price due to a downgrade in analyst recommendation, despite a generally positive market day for equities [1]. Group 1: Analyst Downgrade - UBS analyst David Dai changed his recommendation for Iovance from buy to neutral and significantly lowered the price target from $17 to $2 per share [2]. - This downgrade followed the release of the company's latest quarterly earnings, which provided insights into its performance [4]. Group 2: Product Performance Concerns - Sales of Iovance's leading product, the advanced melanoma drug Amtagvi, were reported to be below expectations, indicating a slower commercialization ramp-up [5]. - There are concerns regarding higher drop-out rates for Amtagvi, suggesting potential flaws in patient selection [5]. Group 3: Revenue Guidance and Market Sentiment - The company issued a notable revenue guidance cut in its earnings report, raising concerns among investors about its future performance [6]. - Despite the scientific potential of Iovance and Amtagvi, the current business aspects warrant caution among investors [6].